Novartis: Solid Fundamentals but Balanced Risk-Reward Justify Hold RatingTip Ranks·2 days ago, 09:55 AMNVS-0.64%
10:31 ETFood Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsightprnewswire·2 days ago, 09:32 AMNVS-0.64%RAPT0.00%
Novartis publishes Q2 impact and sustainability update to investorsPUBT·2 days ago, 05:23 AMNVS-0.64%
Novartis: Balanced Upside Potential and Execution Risks Lead Analyst to Maintain Hold Rating Ahead of Key Phase III ReadoutsTip Ranks·2 days ago, 01:15 AMNVS-0.64%
Inside the Healthcare Overhaul: HCA's Payer Headwinds and Novartis's Pipeline PushGlobal Report·Jul 25 at 04:12 AMHCA-2.39%NVS-0.64%
Micro-Cap Purges and Industrial Pivots: The Hidden Overhaul Sweeping Through Q2Global Report·Jul 24 at 04:13 AMET0.00%ROK-2.50%
Tech Pivots to Cloud Mega-Deals as AI Momentum Spills Into BiopharmaGlobal Report·Jul 22 at 04:17 AMAKAM-3.92%GENB-0.46%
Novartis: Buy Rating Reiterated on Q2 Beat, Strong Growth Brands and Pipeline Upside; Price Target Maintained at $140Tip Ranks·Jul 21 at 07:10 PMNVS-0.64%
Novartis AG Stock (NVS) Moved Up by 3.42% on Jul 21: Key Drivers UnveiledTradingKey·Jul 21 at 11:19 AMNVS-0.64%
Novartis CEO shrugs off oral PCSK9 threat amid Q2 growthFiercepharma·Jul 21 at 09:43 AMNVS-0.64%MRK-1.11%
Novartis rises 5% in regular trading as Q2 earnings beat estimatesUS Stock Market Update·Jul 21 at 09:21 AMNVS-0.64%
Novartis Silences Generic Fears With Blowout Quarter, Packed Pipelinebenzinga_article·Jul 21 at 07:21 AMNVS-0.64%
